AXOGEN INC (AXGN) Fundamental Analysis & Valuation

NASDAQ:AXGN • US05463X1063

Current stock price

32.61 USD
+0.86 (+2.71%)
At close:
32.85 USD
+0.24 (+0.74%)
Pre-Market:

This AXGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. AXGN Profitability Analysis

1.1 Basic Checks

  • AXGN had positive earnings in the past year.
  • AXGN had a positive operating cash flow in the past year.
  • In the past 5 years AXGN always reported negative net income.
  • In multiple years AXGN reported negative operating cash flow during the last 5 years.
AXGN Yearly Net Income VS EBIT VS OCF VS FCFAXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -7.08%, AXGN is in the better half of the industry, outperforming 66.14% of the companies in the same industry.
  • AXGN's Return On Equity of -12.19% is fine compared to the rest of the industry. AXGN outperforms 66.67% of its industry peers.
Industry RankSector Rank
ROA -7.08%
ROE -12.19%
ROIC N/A
ROA(3y)-7.67%
ROA(5y)-10.16%
ROE(3y)-14.83%
ROE(5y)-19.41%
ROIC(3y)N/A
ROIC(5y)N/A
AXGN Yearly ROA, ROE, ROICAXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • AXGN has a better Gross Margin (74.31%) than 84.13% of its industry peers.
  • In the last couple of years the Gross Margin of AXGN has remained more or less at the same level.
  • AXGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.55%
GM growth 5Y-1.15%
AXGN Yearly Profit, Operating, Gross MarginsAXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. AXGN Health Analysis

2.1 Basic Checks

  • AXGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AXGN has been increased compared to 1 year ago.
  • AXGN has more shares outstanding than it did 5 years ago.
  • AXGN has a better debt/assets ratio than last year.
AXGN Yearly Shares OutstandingAXGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AXGN Yearly Total Debt VS Total AssetsAXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 10.42 indicates that AXGN is not in any danger for bankruptcy at the moment.
  • AXGN has a better Altman-Z score (10.42) than 90.48% of its industry peers.
  • AXGN has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
  • AXGN has a Debt to Equity ratio (0.38) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 10.42
ROIC/WACCN/A
WACC10.74%
AXGN Yearly LT Debt VS Equity VS FCFAXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • AXGN has a Current Ratio of 5.11. This indicates that AXGN is financially healthy and has no problem in meeting its short term obligations.
  • AXGN has a better Current ratio (5.11) than 75.66% of its industry peers.
  • A Quick Ratio of 3.31 indicates that AXGN has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 3.31, AXGN is doing good in the industry, outperforming 67.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.11
Quick Ratio 3.31
AXGN Yearly Current Assets VS Current LiabilitesAXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. AXGN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 123.08% over the past year.
  • AXGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.21%.
  • The Revenue has been growing by 14.93% on average over the past years. This is quite good.
EPS 1Y (TTM)123.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y17.56%
Revenue growth 5Y14.93%
Sales Q2Q%21.25%

3.2 Future

  • The Earnings Per Share is expected to grow by 43.00% on average over the next years. This is a very strong growth
  • AXGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.85% yearly.
EPS Next Y79.12%
EPS Next 2Y63.28%
EPS Next 3Y49.92%
EPS Next 5Y43%
Revenue Next Year18.41%
Revenue Next 2Y17.38%
Revenue Next 3Y17.47%
Revenue Next 5Y18.85%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AXGN Yearly Revenue VS EstimatesAXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AXGN Yearly EPS VS EstimatesAXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. AXGN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 112.45, which means the current valuation is very expensive for AXGN.
  • 65.61% of the companies in the same industry are more expensive than AXGN, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of AXGN to the average of the S&P500 Index (25.50), we can say AXGN is valued expensively.
  • A Price/Forward Earnings ratio of 62.78 indicates a quite expensive valuation of AXGN.
  • Based on the Price/Forward Earnings ratio, AXGN is valued a bit cheaper than 67.20% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.67. AXGN is valued rather expensively when compared to this.
Industry RankSector Rank
PE 112.45
Fwd PE 62.78
AXGN Price Earnings VS Forward Price EarningsAXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXGN Per share dataAXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • AXGN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as AXGN's earnings are expected to grow with 49.92% in the coming years.
PEG (NY)1.42
PEG (5Y)N/A
EPS Next 2Y63.28%
EPS Next 3Y49.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AXGN Dividend Analysis

5.1 Amount

  • AXGN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AXGN Fundamentals: All Metrics, Ratios and Statistics

AXOGEN INC

NASDAQ:AXGN (3/24/2026, 8:14:58 PM)

Premarket: 32.85 +0.24 (+0.74%)

32.61

+0.86 (+2.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners82.91%
Inst Owner Change3.78%
Ins Owners1.31%
Ins Owner Change1.21%
Market Cap1.69B
Revenue(TTM)225.21M
Net Income(TTM)-15.70M
Analysts83.53
Price Target38.11 (16.87%)
Short Float %5.84%
Short Ratio2.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.4%
Min EPS beat(2)-29.35%
Max EPS beat(2)64.15%
EPS beat(4)2
Avg EPS beat(4)-25.5%
Min EPS beat(4)-222.55%
Max EPS beat(4)85.77%
EPS beat(8)6
Avg EPS beat(8)170.95%
EPS beat(12)10
Avg EPS beat(12)136.01%
EPS beat(16)13
Avg EPS beat(16)114.35%
Revenue beat(2)1
Avg Revenue beat(2)1.52%
Min Revenue beat(2)-0.64%
Max Revenue beat(2)3.69%
Revenue beat(4)2
Avg Revenue beat(4)1.76%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)5.47%
Revenue beat(8)4
Avg Revenue beat(8)1.63%
Revenue beat(12)7
Avg Revenue beat(12)0.95%
Revenue beat(16)8
Avg Revenue beat(16)0.5%
PT rev (1m)2.09%
PT rev (3m)10.22%
EPS NQ rev (1m)25.74%
EPS NQ rev (3m)25.74%
EPS NY rev (1m)5.47%
EPS NY rev (3m)5.65%
Revenue NQ rev (1m)0.82%
Revenue NQ rev (3m)0.82%
Revenue NY rev (1m)2.56%
Revenue NY rev (3m)2.74%
Valuation
Industry RankSector Rank
PE 112.45
Fwd PE 62.78
P/S 7.52
P/FCF N/A
P/OCF 2084.31
P/B 13.14
P/tB 13.86
EV/EBITDA N/A
EPS(TTM)0.29
EY0.89%
EPS(NY)0.52
Fwd EY1.59%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)0.02
OCFY0.05%
SpS4.34
BVpS2.48
TBVpS2.35
PEG (NY)1.42
PEG (5Y)N/A
Graham Number4.02
Profitability
Industry RankSector Rank
ROA -7.08%
ROE -12.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.31%
FCFM N/A
ROA(3y)-7.67%
ROA(5y)-10.16%
ROE(3y)-14.83%
ROE(5y)-19.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.55%
GM growth 5Y-1.15%
F-Score5
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.2%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.11
Quick Ratio 3.31
Altman-Z 10.42
F-Score5
WACC10.74%
ROIC/WACCN/A
Cap/Depr(3y)159.85%
Cap/Depr(5y)427.53%
Cap/Sales(3y)4.76%
Cap/Sales(5y)10.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y79.12%
EPS Next 2Y63.28%
EPS Next 3Y49.92%
EPS Next 5Y43%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y17.56%
Revenue growth 5Y14.93%
Sales Q2Q%21.25%
Revenue Next Year18.41%
Revenue Next 2Y17.38%
Revenue Next 3Y17.47%
Revenue Next 5Y18.85%
EBIT growth 1Y-138.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1019.72%
EBIT Next 3Y175.88%
EBIT Next 5Y106.3%
FCF growth 1Y-43572.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.09%
OCF growth 3YN/A
OCF growth 5YN/A

AXOGEN INC / AXGN Fundamental Analysis FAQ

What is the fundamental rating for AXGN stock?

ChartMill assigns a fundamental rating of 4 / 10 to AXGN.


What is the valuation status for AXGN stock?

ChartMill assigns a valuation rating of 2 / 10 to AXOGEN INC (AXGN). This can be considered as Overvalued.


What is the profitability of AXGN stock?

AXOGEN INC (AXGN) has a profitability rating of 3 / 10.


How financially healthy is AXOGEN INC?

The financial health rating of AXOGEN INC (AXGN) is 5 / 10.


What is the expected EPS growth for AXOGEN INC (AXGN) stock?

The Earnings per Share (EPS) of AXOGEN INC (AXGN) is expected to grow by 79.12% in the next year.